CRISPR Therapeutics
CRISPR Therapeutics' revenue fell 90.6% to $4 million in fiscal 2025. Its operating margin was −18,933.7%, down from −1,250.4% a year earlier. Free cash flow was −$346 million. The diluted share count rose 6.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What CRISPR Therapeutics does
CRISPR Therapeutics develops medicines based on CRISPR/Cas9, a technology for gene editing, which means precisely changing specific pieces of a person's DNA. It is a biopharmaceutical company based in Switzerland, with its work centered on four areas: blood disorders (hemoglobinopathies), in vivo editing (editing cells inside the body), CAR T cell therapies, and regenerative medicine.
Its most advanced product is CASGEVY, developed with its partner Vertex Pharmaceuticals and approved in 2023 as the first CRISPR-based therapy. It treats severe sickle cell disease and transfusion-dependent beta thalassemia, two inherited blood disorders. Doctors edit a patient's own blood stem cells outside the body and then return them. The two companies work together under a collaboration agreement.
Its other programs include gene-edited immune cells for autoimmune diseases and cancer, and an islet cell replacement candidate for Type 1 diabetes. It has funded its work through share sales and partnerships, and says it has incurred operating losses and expects more.
Its biggest risks, as it describes them
- It has incurred significant operating losses and expects them to continue.
- It will need to raise substantial money, which would dilute shareholders.
- The intellectual property behind its core gene editing technology is jointly owned, which limits its rights.
- Vertex, its partner on CASGEVY, has significant control over that lead program.
- Its gene-editing candidates may fail in trials or fail to win regulatory approval.
Income statement
From fiscal 2019 to 2021, earnings per share grew 100.4% a year and net income 137.6% a year, as new shares raised the share count by 41% and diluted each share's earnings. CRISPR Therapeutics then lost money in fiscal 2022, 2023, 2024 and 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 2,379 | 1,815 | 1,694 | 1,904 | 1,976 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 20.2x | 15.3x | 17.5x | 22.1x | 13.3x |
| Quick ratio | 20.2x | 15.3x | 17.5x | 22.1x | 13.3x |
Cash flow
Projections
Project CRISPR Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought CRISPR Therapeutics shares on the open market, and 5 insiders sold $14.5 million, $10.2 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 22, 2026 | James R. KasingerGeneral Counsel and Secretary | Sold plan | 10,400 | $60.24 | $626,496 | Form 4 |
| Sep 17, 2026 | Ali BehbahaniDirector | Sold | 13,679 | $57.09 | $780,934 | Form 4 |
| May 29, 2026 | Naimish PatelChief Medical Officer | Sold | 3,786 | $55.62 | $210,577 | Form 4 |
| Mar 23, 2026 | Samarth KulkarniChief Executive Officer, Director | Sold | 10,020 | $46.78 | $468,736 | Form 4 |
| Mar 23, 2026 | Raju PrasadChief Financial Officer | Sold | 3,708 | $46.78 | $173,460 | Form 4 |
| Mar 23, 2026 | James R. KasingerGeneral Counsel and Secretary | Sold | 3,182 | $46.78 | $148,854 | Form 4 |
| Mar 16, 2026 | Samarth KulkarniChief Executive Officer, Director | Sold | 10,349 | $48.26 | $499,443 | Form 4 |
| Mar 16, 2026 | Raju PrasadChief Financial Officer | Sold | 9,869 | $48.26 | $476,278 | Form 4 |
| Mar 16, 2026 | James R. KasingerGeneral Counsel and Secretary | Sold | 3,450 | $48.26 | $166,497 | Form 4 |
| Mar 16, 2026 | Naimish PatelChief Medical Officer | Sold | 3,150 | $48.26 | $152,019 | Form 4 |
| Mar 11, 2026 | Samarth KulkarniChief Executive Officer, Director | Sold | 9,798 | $52.80 | $517,334 | Form 4 |
| Mar 11, 2026 | James R. KasingerGeneral Counsel and Secretary | Sold | 2,800 | $52.80 | $147,840 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 30,812.8% | −477.7% | −9,946.1% |
| Altman Z'' | 8.86 | 8.57 | 6.42 |
| Accruals ratio | 4.8% | −10.0% | −10.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Fail | Fail |
| F-score | — | — | — |
Compare
Put CRISPR Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| CRISPR Therapeutics | FY25 | −90.6% | −18,933.7% | −9,855.5% | — | — | — | |
| CG Oncology | FY25 | 254.7% | −4,722.1% | −3,279.2% | — | — | 2 | Compare |
| Absci | FY25 | −38.2% | −4,297.0% | −3,358.3% | −162.8% | — | 3 | Compare |
| Prime Medicine | FY25 | 55.3% | −4,498.1% | −3,607.4% | — | — | — | Compare |
| Celldex Therapeutics | FY25 | −78.0% | −18,599.8% | −13,829.1% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 5 | 41 | 3 | 290 | 1 | 915 | 1 | 371 | 37 | 4 |
| Revenue growth | 1,990.7% | 693.9% | −92.4% | 9,169.9% | −99.8% | 127,154.9% | −99.9% | 30,885.5% | −90.0% | −90.6% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 42 | 70 | 114 | 179 | 221 | 341 | 462 | 387 | 310 | 285 |
| Operating income | −68 | −65 | −159 | 47 | −354 | 374 | −673 | −222 | −467 | −665 |
| Net income | −23 | −68 | −165 | 67 | −349 | 378 | −650 | −154 | −366 | −582 |
| Diluted EPS (US$) | −1.89 | −1.71 | −3.44 | 1.17 | −5.29 | 4.70 | −8.36 | −1.94 | −4.34 | −6.47 |
| Diluted shares (millions) | 12 | 40 | 48 | 57 | 66 | 80 | 78 | 79 | 84 | 90 |
| Cash flow | ||||||||||
| Cash from operations | −53 | −70 | −96 | 57 | −238 | 539 | −496 | −260 | −143 | −345 |
| Capital expenditure | 3 | 8 | 3 | 7 | 18 | 82 | 37 | 10 | 2 | 1 |
| Free cash flow | −56 | −78 | −99 | 50 | −257 | 457 | −533 | −270 | −145 | −346 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 11 | 19 | 35 | 44 | 66 | 102 | 98 | 81 | 87 | 72 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 316 | 240 | 457 | 944 | 1,690 | 2,379 | 1,815 | 1,694 | 1,904 | 1,976 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 345 | 271 | 489 | 1,067 | 1,828 | 2,752 | 2,243 | 2,230 | 2,242 | 2,265 |
| Total liabilities | 112 | 84 | 97 | 127 | 164 | 352 | 368 | 347 | 310 | 343 |
| Shareholders' equity | 233 | 188 | 392 | 939 | 1,664 | 2,400 | 1,876 | 1,883 | 1,932 | 1,922 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | −1,319.3% | −157.7% | −5,087.8% | 16.1% | −49,295.6% | 40.8% | −56,190.4% | −60.0% | −1,250.4% | −18,933.7% |
| Net margin | −448.8% | −166.7% | −5,281.1% | 23.1% | −48,520.9% | 41.3% | −54,271.7% | −41.4% | −981.5% | −16,569.8% |
| Free cash flow margin | −1,082.0% | −190.0% | −3,169.4% | 17.3% | −35,705.7% | 50.0% | −44,484.9% | −72.7% | −387.7% | −9,855.5% |
| Rule of 40 (growth + FCF margin) | 908.7% | 503.9% | −3,261.8% | 9,187.1% | −35,805.4% | 127,204.9% | −44,584.8% | 30,812.8% | −477.7% | −9,946.1% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −22.8% | −32.5% | −56.9% | 10.0% | −26.8% | 18.6% | −30.4% | −8.2% | −19.2% | −30.2% |
| Return on assets | −9.2% | −22.2% | −43.4% | 8.6% | −24.1% | 16.5% | −26.0% | −6.9% | −16.4% | −25.8% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |